Pharmicell - Public Comps and Valuation Multiples

Pharmicell Overview

About Pharmicell

Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Founded

1968

HQ

Employees

n/a

Website

pharmicell.com

Sectors

Regenerative Medicine
Biopharmaceuticals
BioTech

Financials

Last FY Revenue $44.8M

Last FY EBITDA $6.5M

EV

$527M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Pharmicell Financials

See Pharmicell valuation multiples based on analyst estimates

Pharmicell P&L

In the most recent fiscal year, Pharmicell reported revenue of $44.8M and EBITDA of $6.5M.

Pharmicell expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Pharmicell valuation multiples based on analyst estimates

	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	XXX	$44.8M	XXX	XXX	XXX
Gross Profit	XXX	$14.7M	XXX	XXX	XXX
Gross Margin	XXX	33%	XXX	XXX	XXX
EBITDA	XXX	$6.5M	XXX	XXX	XXX
EBITDA Margin	XXX	15%	XXX	XXX	XXX
EBIT	XXX	$3.2M	XXX	XXX	XXX
EBIT Margin	XXX	7%	XXX	XXX	XXX
Net Profit	XXX	$4.4M	XXX	XXX	XXX
Net Margin	XXX	10%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Pharmicell including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Pharmicell achieved $44.8M in revenue and $6.5M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	Analyst estimates available to subscribers	$44.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$14.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	32.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$6.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	14.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$3.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	7.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$4.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	9.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Pharmicell

This financial data table provides comprehensive performance metrics for Pharmicell, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Pharmicell reported $44.8M in total revenue.
Fiscal year EBITDA was $6.5M.
The company maintained a gross profit margin of 32.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 14.5%.
Net profit margin reached 9.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Pharmicell. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Pharmicell Stock Performance

Pharmicell has current market cap of KRW 792B (or $547M), and EV of KRW 763B (or $527M).

Market Cap Evolution

Pharmicell Stock Data

As of January 19, 2026, Pharmicell's stock price is KRW 13200 (or $9).

See Pharmicell trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$527M	$547M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Pharmicell Valuation Multiples

Pharmicell's trades at 11.8x EV/Revenue multiple, and 81.0x EV/EBITDA.

See valuation multiples for Pharmicell and 15K+ public comps

Pharmicell Financial Valuation Multiples

As of January 19, 2026, Pharmicell has market cap of $547M and EV of $527M.

Equity research analysts estimate Pharmicell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pharmicell's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$547M	XXX	$547M	XXX	XXX	XXX
EV (current)	$527M	XXX	$527M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	11.8x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	81.0x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	164.0x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	125.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-908.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Pharmicell Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Pharmicell Margins & Growth Rates

Pharmicell's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Pharmicell's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pharmicell's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Pharmicell and other 15K+ public comps

Pharmicell Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	2%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	12%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	26%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial